Short answer
Oruka Therapeutics, Inc. (ORKA) filed an 8-K current report with the SEC on August 24, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Todd Edwards appointed Chief Commercial Officer effective August 24, 2026, adding commercialization leadership from Arcutis, Incyte, and UCB.
Oruka Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Todd Edwards appointed Chief Commercial Officer effective August 24, 2026, adding commercialization leadership from Arcutis, Incyte, and UCB
- Annual base salary $525,000, with discretionary bonus targeted at 40% of salary
- Equity grant covers 20,000 option shares and 100,000 RSUs, supporting retention through multi-year vesting
- $200,000 signing bonus, subject to prorated repayment for early resignation or termination for cause
- Change-in-control protection includes severance equal to 1.0 times salary plus target bonus and full time-based equity acceleration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oruka Therapeutics, Inc. 8-K filings
Get the next ORKA 8-K as it lands
Follow ORKA for push alerts, or ask the research agent what this filing means.